A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination With Three Different Methods of Administration of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Modified-Bolus 5-FU (Day 1 and 8), and Oral Capecitabine (Day 1-14); With Celecoxib Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer Study Amended April 23, 2004 to Include Bevacizumab

Trial Profile

A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination With Three Different Methods of Administration of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Modified-Bolus 5-FU (Day 1 and 8), and Oral Capecitabine (Day 1-14); With Celecoxib Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer Study Amended April 23, 2004 to Include Bevacizumab

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Bevacizumab; Capecitabine; Celecoxib; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BICC-C
  • Most Recent Events

    • 20 Oct 2007 Results published in JCO.
    • 03 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top